Keyword Analysis & Research: ulcerative colitis treatment algorithm

gastrojournal.org

https://www.gastrojournal.org/article/S0016-5085(20)30018-4/fulltext

WEBJan 13, 2020 · In adult outpatients with moderate to severe ulcerative colitis who have previously been exposed to infliximab, particularly those with primary nonresponse, the AGA suggests using ustekinumab or tofacitinib, rather than vedolizumab or adalimumab, for induction of remission.

DA: 27 PA: 41 MOZ Rank: 95

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171548/

WEBAug 17, 2020 · The choice of treatment for ulcerative colitis is generally based on the pattern of involvement of the disease and the degree of its clinical activity (figure 1). Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a pillar of pharmacotherapy for ulcerative colitis.

DA: 51 PA: 96 MOZ Rank: 58

gastrojournal.org

https://www.gastrojournal.org/article/S0016-5085(18)35407-6/fulltext

WEBBalsalazide is the better-tolerated diazo-bonded 5-ASA, with similar effectiveness to standard-dose mesalamine for induction and better efficacy for maintenance. Therefore, either standard-dose mesalamine or balsalazide are appropriate for treatment of extensive mild–moderate UC.

DA: 7 PA: 14 MOZ Rank: 45

lww.com

https://journals.lww.com/ajg/Fulltext/2019/03000/ACG_Clinical_Guideline__Ulcerative_Colitis_in.10.aspx

WEBA comprehensive assessment of severity of UC should include predictors of an aggressive disease course, need for colectomy, and response to therapies. Several prospective cohorts have examined the role of clinical parameters, genetics, and serologic markers in predicting the need for colectomy in UC ( 69,70 ).

DA: 25 PA: 76 MOZ Rank: 72

gastrojournal.org

https://www.gastrojournal.org/article/S0016-5085(20)30018-4/pdf

WEBulcerative colitis, the AGA recommends using infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ustekinumab over no treatment. (Strong recommendation, moderate quality evidence) The panel recommends treating adult outpatients with moderate to severe UC with infliximab, adalimumab, goli-

DA: 11 PA: 92 MOZ Rank: 14

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191814/

WEBIn October 2020 and January 2021, a group of clinical experts in the field of inflammatory bowel disease (IBD) convened virtually to discuss current ulcerative colitis (UC) guidelines and how to interpret them in the context of the evolving treatment paradigms and …

DA: 16 PA: 50 MOZ Rank: 100

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858922/

WEBIn patients with extensive mild-moderate ulcerative colitis, the AGA recommends using either standard dose mesalamine (2–3 grams/day) or diazo-bonded 5-ASA rather than low dose mesalamine, sulfasalazine or no treatment.

DA: 92 PA: 83 MOZ Rank: 55

nih.gov

https://pubmed.ncbi.nlm.nih.gov/30840605/

WEBMar 9, 2019 · Abstract. Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology.

DA: 88 PA: 2 MOZ Rank: 53

fascrs.org

https://fascrs.org/getattachment/Healthcare-Providers/Education/Clinical-Practice-Guidelines/2021-Ulcerative-Colitis-CPG.pdf?lang=en-US

WEBUlcerative colitis (UC) is an idiopathic chronic inflamma-tory condition that afects the mucosa lining the colon and rectum that, for unknown reasons, continues to increase in incidence with nearly 3.1 million people afected in the United States alone.1 Patients most often present in 2 gen-eral age categories, between about ages 15 and 30 or 55 ...

DA: 88 PA: 87 MOZ Rank: 26

mayoclinic.org

https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/diagnosis-treatment/drc-20353331

WEBTreatment. Ulcerative colitis treatment usually involves either medication therapy or surgery. Several categories of medications may be effective in treating ulcerative colitis. algorithm

algorithm

DA: 40 PA: 59 MOZ Rank: 47